The evolution of botulinum neurotoxin type A for cosmetic applications

References

• Schantz E. J., Johnson E. A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992; 56: 80–99
   PubMedGoogle Scholar
• BOTOX Cosmetic [package insert], Allergan, Inc.: Irvine, CA
   Google Scholar
• BOTOX [package insert], Allergan, Inc: Irvine, CA
   Google Scholar
• Dysport [package insert], Ipsen Ltd: Slough, Berkshire, UK
   Google Scholar
• MYOBLOC [package insert], Solstice Neurosciences, Inc: South San Francisco, CA
   Google Scholar
• Xeomin [package insert], Merz Pharmaceuticals: Frankfurt/Main, Germany
   Google Scholar
• Carruthers J. D. A., Carruthers J. A. Treatment of glabellar frown lines with C. botulinum‐A exotoxin. J Dermatol Surg Oncol 1992; 18: 17–21
   PubMed Web of Science ®Google Scholar
• The American Society for Aesthetic Plastic Surgery. Cosmetic Surgery National Data Bank. 2006 statistics. The American Society for Aesthetic Plastic Surgery, Inc. Accessed March 16, 2007. URL: http://www.surgery.org/download/2006stats.pdf
   Google Scholar
• Schantz E. J. Historical perspective. Therapy with botulinum toxin, J Jankovic, M Hallet. Marcel Dekker, Inc, New York 1994; xxiii–xxvi
   Google Scholar
• Scott A. B., Rosenbaum A., Collins C. C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973; 12: 924–7
   PubMedGoogle Scholar
• Scott A. B. Development of botulinum toxin therapy. Dermatol Clin 2004; 22: 131–3
   PubMed Web of Science ®Google Scholar
• Scott A. B. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981; 79: 734–70
   PubMedGoogle Scholar
• Scott A., Kennedy R. A., Stubbs H. A. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985; 103: 347–50
   PubMedGoogle Scholar
• Carruthers J. D. A. Ophthalmologic use of botulinum A exotoxin. Can J Ophthalmol 1985; 20: 135–41
   PubMed Web of Science ®Google Scholar
• Carruthers J., Stubbs H. A. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age‐related lower eyelid entropion. Can J Neurol Sci 1987; 14: 42–5
   PubMed Web of Science ®Google Scholar
• Tsui J. K., Eisen A., Mak E., Carruthers J., Scott A., Calne D. B. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985; 12: 314–16
   PubMed Web of Science ®Google Scholar
• Brin M. F., Fahn S., Moskowitz C., Friedman A., Shale H. M., Greene P. E., et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987; 2: 237–54
   PubMed Web of Science ®Google Scholar
• Clark R. P., Berris C. E. Botulinum toxin: A treatment for facial asymmetry caused by facial nerve paralysis. Plast Reconstr Surg 1989; 84: 353–5
   PubMed Web of Science ®Google Scholar
• Blitzer A., Brin M. F., Keen M. S., Aviv J. E. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993; 119: 1018–22
   PubMed Web of Science ®Google Scholar
• Keen M., Blitzer A., Aviv J., Binder W., Prystowsky J., Smith H., et al. Botulinum toxin A for hyperkinetic facial lines: Results of a double‐blind, placebo‐controlled study. Plast Reconstr Surg 1994; 94: 94–9
   PubMed Web of Science ®Google Scholar
• Hankins C. L., Strimling R., Rogers G. S. Botulinum A toxin for glabellar wrinkles. Dose and response. Dermatol Surg 1998; 24: 1181–3
   PubMed Web of Science ®Google Scholar
• Carruthers A., Carruthers J., Said S. Dose‐ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31: 414–22
   PubMed Web of Science ®Google Scholar
• Carruthers A., Carruthers J. Prospective, double‐blind, randomized, parallel‐group, dose‐ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005; 31: 1297–303
   PubMed Web of Science ®Google Scholar
• Carruthers A., Carruthers J., Cohen J. A prospective, double‐blind, randomized, parallel‐group, dose‐ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol Surg 2003; 29: 461–7
   PubMed Web of Science ®Google Scholar
• Lowe N. J., Ascher B., Heckmann M., Kumar C., Fraczek S., Eadie N., on behalf of the Botox Facial Aesthetics Study Team. Double‐blind, randomized, placebo‐controlled, dose–response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31: 257–62
   PubMed Web of Science ®Google Scholar
• Carruthers J. A., Lowe N. J., Menter M. A., Gibson J., Nordquist M., Mordaunt J., , for the BOTOX Glabellar Lines I Study Group, et al. A multicenter, double‐blind, randomized, placebo‐controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840–9
   PubMed Web of Science ®Google Scholar
• Carruthers J. D., Lowe N. J., Menter M. A., Gibson J., Eadie N., for the Botox Glabellar Lines II Study Group. Double‐blind, placebo‐controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112: 1089–98
   PubMed Web of Science ®Google Scholar
• Schantz E. J., Johnson E. A. Botulinum toxin: The story of its development for the treatment of human disease. Perspect Biol Med 1997; 40: 317–27
   PubMed Web of Science ®Google Scholar
• Foran P. G., Mohammed N., Lisk G. O., Nagwaney S., Lawrence G. W., Johnson E., et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 2003; 278: 1363–71
   PubMed Web of Science ®Google Scholar
• Aoki K. R. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin 2005; 45: 25–37
   PubMedGoogle Scholar
• Schantz E. J., Johnson E. A. Preparation and characterization of botulinum toxin type A for human treatment. Therapy with botulinum toxin, J Jankovic, M Hallet. Marcel Dekker, Inc, New York 1994; 41–9
   Google Scholar
• Hambleton P., Capel B., Bailey N., Heron N., Crooks A., Melling J., . Production, purification and toxoiding of Clostridium botulinum type A toxin. Biomedical aspects of botulism, G. E Jr Lewis, P. S Angel, et al. Academic Press, New York 1981; 247–60
   Google Scholar
• Ascher B., Klap P., Marion M. H., Chanteloub F. Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles. An initial study [in French]. Ann Chir Plast Esthet 1995; 40: 67–76
   PubMedGoogle Scholar
• Rzany B., Ascher B., Fratila A., Monheit G. D., Talarico S., Sterry W. Efficacy and safety of 3‐ and 5‐injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142: 320–6
   PubMedGoogle Scholar
• Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., Santini J. A multicenter, randomized, double‐blind, placebo‐controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223–33
   PubMed Web of Science ®Google Scholar
• Ascher B., Zakine B., Kestemont P., Baspeyras M., Bougara A., Niforos F., et al. Botulinum toxin A in the treatment of glabellar lines: Scheduling the next injection. Aesthetic Surg J 2005; 25: 365–75
   PubMedGoogle Scholar
• Monheit G., Carruthers A., Brandt F., Rand R. A randomized, double‐blind, placebo‐controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg 2007; 33((special issue))S51–9
   PubMedGoogle Scholar
• Rzany B., Dill‐Müller D., Grablowitz D., Heckmann M., Caird D., on behalf of the German–Austrian Retrospective Study Group. Repeated botulinum toxin A injections for the treatment of lines in the upper face: A retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 2007; 33((special issue))S18–25
   PubMedGoogle Scholar
• Lowe P., Patnaik R., Lowe N. Comparison of two formulations of botulinum type A toxin for the treatment of glabellar lines: A double‐blind, randomized, study. J Am Acad Dermatol 2006; 55: 975–80
   PubMed Web of Science ®Google Scholar
• Carruthers A., Carruthers J., Flynn T. C., Leong M. S. Dose‐finding, safety, and tolerability study of Botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg 2007; 33((special issue))S60–8
   PubMedGoogle Scholar
• Lowe N. J., Yamauchi P. S., Lask G. P., Patnaik R., Moore D. Botulinum toxin types A and B for brow furrows: Preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002; 4: 15–18
   PubMedGoogle Scholar
• Markey A. C. Dysport. Dermatol Clin 2004; 22: 213–19
   PubMed Web of Science ®Google Scholar
• Foster K. A., Bigalke H., Aoki K. R. Botulinum neurotoxin – from laboratory to bedside. Neurotox Res 2006; 9((2–3))133–40
   PubMedGoogle Scholar
• Trindade de Almeida A., Marques E., de Almeida J., Cunha T., Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33((special issue))S37–43
   PubMedGoogle Scholar
• Lew H., Yun Y. S., Lee S. Y., Kim S. J. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica 2002; 216: 50–4
   PubMed Web of Science ®Google Scholar
• De Boulle K., Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytids. Poster presented at the 31st Annual Hawaii Dermatology Seminar, March 3–9, 2007, Wailea, Maui, HI
   Google Scholar
• Carruthers J., Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin 2004; 22: 151–8
   PubMed Web of Science ®Google Scholar
• Kane M. A. Nonsurgical treatment of platysmal bands with injection of botulinum toxin type A revisited. Plast Reconstr Surg 2003; 112((5 suppl))125S–6
   PubMedGoogle Scholar
• Carruthers J., Fagien S., Matarasso S. L., the Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 2004; 114((6 suppl))1S–22
   PubMedGoogle Scholar
• Beer K., Yohn M., Closter J. A double‐blinded, placebo‐controlled study of Botox® for the treatment of subjects with chin rhytids. J Drugs Dermatol 2005; 4: 417–22
   PubMedGoogle Scholar
• Ahn J., Horn C., Blitzer A. Botulinum toxin for masseter reduction in Asian patients. Arch Facial Plast Surg 2004; 6: 188–91
   PubMedGoogle Scholar
• Brandt F. S., Bellman B. Cosmetic use of botulinum A exotoxin for the aging neck. Dermatol Surg 1998; 24: 1232–4
   PubMed Web of Science ®Google Scholar
• Benedetto A. Asymmetrical smiles corrected by botulinum toxin serotype A. Dermatol Surg 2007; 33((special issue))S32–6
   PubMedGoogle Scholar
• Carruthers J., Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX‐A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: Treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX‐A. Dermatol Surg 2003; 29: 802–9
   PubMed Web of Science ®Google Scholar
• Carruthers J., Carruthers A., Dessain A. Botulinum toxin type A treatment of upper facial sites: Patient‐reported outcomes. Dermatol Surg 2007; 33((special issue))S10–17
   PubMedGoogle Scholar
• Fagien S., Cox S. E., Finn J. C., Werschler W. P., Kowalski J. W. Patient‐reported outcomes with botulinum toxin type A treatment of glabellar rhytids: A double‐blind, randomized, placebo‐controlled study. Dermatol Surg 2007; 33((special issue))S2–9
   PubMedGoogle Scholar
• Carruthers A., Carruthers J., Cox S. E., Fagien S., Patients' assessment of age‐related appearance after botulinum toxin type A treatment of upper facial rhytids: Results across 6 clinical studies. Poster presented at the American Academy of Dermatology 65th Annual Meeting, February 2–6, 2007, Washington, DC; Poster P2915
   Google Scholar
• Carruthers A., Carruthers J., Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: Does it matter?. Dermatol Surg 2007; 33((special issue))S97–104
   PubMedGoogle Scholar
• Sycha T., Kotzailias N., Kranz G., Trautinger F., Schnider P., Auff E. UV‐B irradiation attenuates dermal effects of botulinum toxin A: A randomized, double‐blind, placebo‐controlled study. Dermatol Surg 2007; 33((special issue))S92–6
   PubMedGoogle Scholar
• Lear W., Kessler E., Solish N., Glaser D. A. An epidemiological study of hyperhidrosis. Dermatol Surg 2007; 33((special issue))S69–75
   PubMedGoogle Scholar
• Goldman A. Treatment of axillary and palmar hyperhidrosis with botulinum toxin. Aesthetic Plast Surg 2000; 24: 280–2
   PubMed Web of Science ®Google Scholar
• Lowe N. J., Yamauchi P. S., Lask G. P., Patnaik R., Iyer S. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: A double‐blind, randomized, placebo‐controlled trial. Dermatol Surg 2002; 28: 822–7
   PubMed Web of Science ®Google Scholar
• Naumann M., Lowe N. J., Kumar C. R., Hamm H., Hyperhidrosis Clinical Investigators Group. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: A prospective study. Arch Dermatol 2003; 139: 731–6
   PubMedGoogle Scholar
• Solish N., Benohanian A., Kowalski J. W., on behalf of the Canadian Dermatology Study Group on Health‐Related Quality of Life in Primary Axillary Hyperhidrosis. Prospective open‐label study of botulinum toxin type A in patients with axillary hyperhidrosis: Effects on functional impairment and quality of life. Dermatol Surg 2005; 31: 405–13
   PubMed Web of Science ®Google Scholar
• Heckmann M., Kütt S., Dittmar S., Hamm H. Making scents: Improvement of olfactory profile after botulinum toxin‐A treatment in healthy individuals. Dermatol Surg 2007; 33((special issue))S81–7
   PubMedGoogle Scholar
• Talarico‐Filho S., Mendonca Do Nascimento M., Sperandeo De Macedo F., De Sanctis Pecora C. A double‐blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 2007; 33((special issue))S44–50
   PubMedGoogle Scholar